The Effects of Mirtazapine Versus Placebo on Alcohol Consumption in Male Alcohol High Consumers
NCT ID: NCT00874003
Last Updated: 2009-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
59 participants
INTERVENTIONAL
2004-04-30
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial
NCT02646449
Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism
NCT00452543
Reducing Alcohol Use in Depressed Patients
NCT00183079
Acamprosate in Alcoholics With Comorbid Anxiety or Depression
NCT00330174
Melatonin Use for Sleep Problems in Alcohol Dependent Patients
NCT03043443
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
mirtazapine, tablet, 30 mg
n=29
mirtazapine
oral tablet, 30 mg daily
sugar pill
n=30
placebo
oral tablet, 1 daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mirtazapine
oral tablet, 30 mg daily
placebo
oral tablet, 1 daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* male sex
* alcohol high consumption
* signed informed consent
Exclusion Criteria
* severe somatic disorders
* inadequate knowledge of the Swedish language
18 Years
65 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sahlgrenska University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Addiction Biology Unit, Sahlgrenska University Hospital, Sweden
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrea deBejczy, MD
Role: STUDY_DIRECTOR
Addiction Biology Unit
Bo Söderpalm, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Addiction Biology Unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Addiction Biology Unit
Gothenburg, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GOTABU-BO1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.